Anxiolytic-like actions of buspirone in a runway model of intravenous cocaine self-administration

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 2, 2006, Pages 393-399

  Ettenberg, Aaron ^a   Bernardi, Rick E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anxiety; Approach avoidance conflict; Drug reward; Retreats; Serotonin

Indexed keywords

BUSPIRONE; COCAINE; DRUG VEHICLE; SEROTONIN 1A AGONIST;

AMBIVALENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; AVERSION; AVOIDANCE BEHAVIOR; CONFLICT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; EXPERIMENTAL MODEL; FOOTSHOCK; LOW DRUG DOSE; MALE; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; RAT; RUNNING; STIMULUS RESPONSE; TASK PERFORMANCE; TRAINING; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; BUSPIRONE; COCAINE; INJECTIONS, INTRAVENOUS; MALE; RATS; RECEPTOR, SEROTONIN, 5-HT1A; REWARD; SELF ADMINISTRATION; SEROTONIN AGONISTS;

ANIMALIA; RATTUS NORVEGICUS;

EID: 33845284516     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.09.007     Document Type: Article

References (84)

1. Abrams J.K., Johnson P.L., Hollis J.H., and Lowry C.A. Anatomic and functional topography of the dorsal raphe nucleus. Ann N Y Acad Sci 1018 (2004) 46-57
2. Abrams J.K., Johnson P.L., Hay-Schidt A., Mikkelsen J.D., Shekkar A., and Lowry C.A. Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience 133 (2005) 983-997
3. Angrini M., Leslie J.C., and Shepard R.A. Effects of propranolol, buspirone, pCPA, reserpine, and chlordiazepoxide on open-field behavior. Pharmacol Biochem Behav 59 (1998) 387-397
4. Anthony J.C., Tien A.Y., and Petronis K.R. Epidemiologic evidence on cocaine use and panic attacks. Am J Epidemiol 129 (1989) 543-549
5. Apter J.T., and Allen L.A. Buspirone: future directions. J Clin Psychopharmacol 19 (1999) 86-93
6. Argyropoulous A.V., Sandford J.J., and Nutt D.J. The psychobiology of anxiolytic drugs part 2: pharmacological treatments of anxiety. Pharmacol Ther 88 (2000) 213-227
7. Bardo M.T., Rowlett J.K., and Harris M.J. Conditioned place preference using opiate and stimulant drugs: a meta-analysis. Neurosci Biobehav Rev 19 (1995) 39-51
8. Benvenga M.J., and Leander J.D. Anticonflict effects of 5HT(1A(agonists in pigeons are dependent on the level of response suppression. Behav Pharmacol 7 (1996) 540-550
9. Bohm C., Placchi M., Stallone F., Gammans R.E., and Alms D.R. A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety. J Clin Psychopharmacol 10 (1990) 38S-42S [suppl]
10. Bond A.J., Wingrove J., Baylis M., and Dalton J. Buspirone decreases physiological reactivity to unconditioned and conditioned aversive stimuli. Psychopharmacology 165 (2003) 291-295
11. Calcagnetti D.J., Keck B.J., Quatrella L.A., and Schechter M.N. Blockade of cocaine-induced conditioned place preference: relevance to cocaine abuse therapeutics. Life Sci 56 (1995) 475-483
12. Carey R.J., DePalma G., Damianopoulos E., Shanahan A., Muller C.P., and Huston J.P. Pharmacological inhibition of DA-and 5-HT activity blocks spontaneous and cocaine-activated behavior: reversal by chronic cocaine treatment. Brain Res 1047 (2005) 194-204
13. Carey R.J., DePalma G., Damianopoulos E., Shanahan A., Muller C.P., and Huston J.P. Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects. Brain Res 1034 (2005) 162-171
14. Carr G.D., Fibiger H.C., and Phillips A.G. Conditioned place preference as a measure of drug reward. In: Liebman J.M., and Cooper S.J. (Eds). The neuropharmacological basis of reward (1989), Clarendon Press, Oxford 264-319
15. Cervo L., Munoz C., Bertaglia A., and Samanin R. Alnespirone and buspirone have anxiolytic-like effects in a conflict procedure in rats stimulating 5-HT(1A) receptors. Behav Pharmacol 11 (2000) 153-160
16. Chang Y.-.H., and Liao R.-M. Identification of anxiogenic stimuli for behavioral performance in the elevated T-maze. Chin J Psychol 47 (2005) 138-155
17. Chaouloff F. Serotonin, stress and corticoids. J Psychopharmacol 14 (2000) 139-151
18. Cornelius J.R., Bukstein O., Salloum I., and Clark D. Alcohol and psychiatric comorbidity. Recent Dev Alcohol 16 (2003) 361-374
19. Costall B., Kelly M.E., Naylor R.J., and Onaivi E.S. Actions of buspirone in a putative model of anxiety in the mouse. J Pharm Pharmacol 40 (1988) 494-500
20. Costall B., Kelly M.E., Naylor R.J., and Onaivi E.S. The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav 33 (1989) 197-203
21. C.L. Czachowski. Ethanol-seeking and self-administration in a runway paradigm. Digital Dissertation 1998; Publ # AAT 9840766.
22. Dekeyne A., Brocco M., Adhumeau A., Gobert A., and Millan M.J. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents. Psychopharmacology (Berl) 152 (2000) 55-66
23. Dworkin S.I., Bimle C., and Miyauchi T. Differential effects of pentobarbital and cocaine on punished and nonpunished responding. J Exp Anal Behav 51 (1989) 173-184
24. Eison A.S., and Eison M.S. Serotonergic mechanisms in anxiety. Prog Neuropsychopharmacol Biol Psychiatry 18 (1994) 47-62
25. Ettenberg A. Opponent process properties of self-administered cocaine. Neurosci Biobehav Rev 278 (2004) 721-728
26. Ettenberg A., and Camp C.H. Haloperidol induces a partial reinforcement extinction effect in rats: implications for a dopamine involvement in food reward. Pharmacol Biochem Behav 25 (1986) 813-821
27. Ettenberg A., and Camp C.H. A partial reinforcement extinction effect in water-reinforced rats intermittently treated with haloperidol. Pharmacol Biochem Behav 25 (1986) 1231-1235
28. Ettenberg A., and Geist T.D. An animal model for investigating the anxiogenic properties of self-administered cocaine. Psychopharmacology 103 (1991) 455-461
29. Ettenberg A., and Geist T.D. Qualitative and quantitative differences in the operant runway behavior of cocaine and heroin reinforced rats. Pharmacol Biochem Behav 44 (1993) 191-198
30. Ettenberg A., Raven M.A., Danluck D.A., and Necessary B.D. Evidence for opponent-process actions of intravenous cocaine. Pharmacol Biochem Behav 64 (1999) 507-512
31. Evenden J.L. The effect of 5-HT1A receptor agonists on locomotor activity in the guinea-pig. Br J Pharmacol 112 (1994) 861-866
32. Fibiger H.C., Phillips A.G., and Brown E.E. The neurobiology of cocaine-induced reinforcement. Ciba Found Symp 166 (1992) 96-111
33. Filip M., Frankowska M., Zaniewska M., Golda A., and Przegalinski E. The serotonergic system and its role in cocaine addiction. Pharmacol Rep 57 (2005) 685-700
34. Fischman M.W., and Schuster C.R. Cocaine self-administration in humans. Fed Proc 41 (1982) 241-246
35. Folton R.W., and Fischman M.W. Cocaine self-administration research: treatment implications. NIDA Res Monogr 145 (1994) 139-162
36. Fontana D.J., and Commissaris R.L. Effects of cocaine on conflict behavior in the rat. Life Sci 45 (1989) 819-827
37. Fulton B., and Brogden R.N. Buspirone, an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 7 (1997) 68-88
38. Geist T.D., and Ettenberg A. A simple method for studying intravenous drug reinforcement in a runway. Pharmacol Biochem Behav 36 (1990) 703-706
39. Geist T.D., and Ettenberg A. Concurrent positive and negative goal box events produce runway behaviors comparable to those of cocaine-reinforced rats. Pharmacol Biochem Behav 57 (1997) 145-150
40. Gill B.M., Knapp C.M., and Kornetsky C. The effects of cocaine on the rate independent brain stimulation reward threshold in the mouse. Pharmacol Biochem Behav 79 (2004) 165-170
41. Gilliss B., Malanga C.J., Pieper J.O., and Carlezon Jr. W.A. Cocaine and SKF-82958 potentiate brain stimulation reward in Swiss-Webster mice. Psychopharmacology (Berl) 163 (2002) 238-248
42. Goa K.L., and Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32 (1986) 114-129
43. Graeff F.G. On serotonin and experimental anxiety. Psychopharmacology 163 (2002) 467-476
44. Griebel G. 5-hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65 (1995) 319-395
45. Guzman D., and Ettenberg A. Heroin attenuates the negative consequences of cocaine in a runway model of self-administration. Pharmacol Biochem Behav 79 (2004) 317-324
46. Hayase T., Yamamoto Y., and Yamamoto K. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. Behav Pharmacol 16 (2005) 395-404
47. Hellewell J.S., Guimaraes F.S., Wang M., and Deakin J.F. Comparison of buspirone with diazepam and fluvoxamine on aversive classical conditioning in humans. J Psychopharmacol 13 (1999) 122-127
48. Jelen P., Soltysik S., and Zagrodzka J. 22-kHz ultrasonic vocalization in rats as an index of anxiety but not fear: behavioral and pharmacological modulation of affective states. Behav Brain Res 141 (2003) 63-72
49. Knackstedt L.A., and Ettenberg A. Ethanol consumption reduces the adverse consequences of self-administered intravenous cocaine in rats. Psychopharmacology 178 (2005) 143-150
50. Knackstedt L.A., Samimi M.M., and Ettenberg A. Evidence for opponent-process actions of intravenous cocaine and cocaethylene. Pharmacol Biochem Behav 72 (2002) 931-936
51. Koe B.K. Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J Pharmacol Exp Ther 199 (1976) 649-661
52. Koek W., Patoiseau J.F., Assie M.B., Cosi C., Kleven M.S., Dupont-Passelaigue E., et al. F-11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J Pharmacol Exp Ther 287 (1998) 266-283
53. Lee S.T., Park J.H., and Kim M. Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study. Headache 45 8 (2005) 1004-1011
54. Lopez H.H., Olster D.H., and Ettenberg A. Sexual motivation in the male rat: the role of primary incentives and copulatory experience. Horm Behav 36 (1999) 176-185
55. Lynch W.J., Sughondhabirom A., Pittman B., Gueorguieva R., Kalayasiri R., Joshua D., et al. A paradigm to investigate the regulation of cocaine self-administration in human cocaine users: a randomized trial. Psychopharmacology (Berl) 185 (2006) 306-314
56. Malec T.S., Malec E.A., and Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 20 (1996) 853-858
57. Mantsch J.R., and Goeders N.E. Generalization of a restraint-induced discriminative stimulus to cocaine in rats. Psychopharmacology (Berl) 135 (1998) 423-426
58. Martin J.R., Moreau J.L., Jenck F., and Cumin R. Acute and chronic administration of buspirone fails to yield anxiolytic-like effects in mouse operant punishment paradigm. Pharmacol Biochem Behav 46 (1993) 905-910
59. Meneses A., and Hong E. Modification of the anxiolytic effects of 5-HT1A agonists by shock intensity. Pharmacol Biochem Behav 46 (1993) 569-573
60. Mignon L., and Wolf W.A. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology 163 (2002) 85-94
61. Millan M.J., Hjorth S., Samanin R., Schreiber R., Jaffard R., De Ladonchamps B., et al. S-15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J Pharmacol Exp Ther 282 (1997) 148-161
62. Miller N.E. Experimental studies of conflict. In: Hunt I.Mc.V. (Ed). Personality and behavior disorders (1944), Ronald Press, New York 431-465
63. Muller C.P., Thonnessen H., Jocham G., Barros M., Tomaz C., Carey R.J., et al. Cocaine-induced 'active immobility' and its modulation by the serotonin 1A receptor. Behav Pharmacol 15 (2004) 481-493
64. Newman-Tancredi A., Gavaudan S., Conte C., Chaput C., Touzard M., Verriele L., et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol 355 (1998) 245-256
65. Paine T.A., Jackman S.L., and Olmstead M.C. Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol 13 (2002) 511-523
66. Pecknold J.C. Serotonin 5-HT 1A agonists: a comprehensive review. CNS Drugs 2 (1994) 234-251
67. Pokk P., and Zharkovsky A. The effects of buspirone on the behavior of control and stressed mice. J Physiol Pharmacol 49 (1998) 175-185
68. Porrino L.J., Daunais J.B., Smith H.R., and Nader M.A. The expanding effects of cocaine: studies in a nonhuman primate model of cocaine self-administration. Neurosci Biobehav Rev 27 (2004) 813-820
69. Rakel R.E. Long term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J 83 (1990) 194-198
70. Raven M.A., Necessary B.D., Danluck D.A., and Ettenberg A. Comparison of the reinforcing and anxiogenic effects of intravenous cocaine and cocaethylene. Exp Clin Psychopharmacol 8 (2000) 117-124
71. Risbrough V.B., Brodkin J.D., and Geyer M.A. GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology 28 (2003) 654-663
72. Ritz M.C., Cone E., and Kuhar M.J. Cocaine inhibition of ligand binding at dopamine, norepinephrine and serotonin transporters: a structure activity study. Life Sci 46 (1990) 635-645
73. Rogerio R., and Takahashi R.N. Anxiogenic properties of cocaine in the rat evaluated with the elevated plus-maze. Pharmacol Biochem Behav 43 (1992) 631-633
74. Sanger D.J. Effects of buspirone and elated compounds on suppressed operant responding in rats. J Pharmacol Exp Ther 254 (1990) 420-427
75. Schreiber R., Brocco M., de Ladonchamps B.L., and Millan M.J. Involvement of 5-HT1A receptors in the anxiolytic action of S 14671 in the pigeon conflict test. Pharmacol Biochem Behav 51 (1995) 211-215
76. Sena L.M., Bueno C., Pobbe R.L., Andrade T.G., Zangrossi Jr. H., and Viana M.B. The dorsal raphe nucleus exerts opposed control on generalized anxiety and panic-related defensive responses in rats. Behav Brain Res 142 (2003) 125-133 [Erratum in: Behav Brain Res 2003;145:233]
77. Simon P., Dupuis R., and Constentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res 61 (1994) 59-64
78. Singha A.K., McCance-Katz E.F., Heck S.A., Kosten T.R., and Oliveto A. Individual differences in humans responding under a cocaine discrimination procedure: discriminators versus nondiscriminators. Exp Clin Psychopharmacol 7 (1999) 391-398
79. Walsh S.L., and Cunningham K.A. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology (Berl) 130 (1997) 41-58
80. Washton A.M., and Gold M.S. Chronic cocaine abuse: evidence for adverse effects on health and functioning. Psychiatr Ann 14 (1984) 733-743
81. Williamson S., Gossop M., Powis B., Griffiths P., Fountain J., and Strang J. Adverse effects of stimulant drugs in a community of drug users. Drug Alcohol Depend 44 (1997) 87-94
82. Winer B.J. Statistical principles in experimental design. 2nd Ed (1971), McGraw-Hill, New York
83. Witkin J.M., and Perez L.A. Comparison of effects of buspirone and gepirone with benzodiazepines and antagonbists of dopamine and serotonin receptors on punished behavior of rats. Behav Pharmacol 1 (1989) 247-254
84. Wolverton W.L. Determinants of cocaine self-administration by laboratory animals. Ciba Found Symp 166 (1992) 149-161